Details
Stereochemistry | RACEMIC |
Molecular Formula | C20H23ClFNO |
Molecular Weight | 347.854 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(CN1CCC(CC2=CC=C(F)C=C2)CC1)C3=CC=C(Cl)C=C3
InChI
InChIKey=GGUSQTSTQSHJAH-UHFFFAOYSA-N
InChI=1S/C20H23ClFNO/c21-18-5-3-17(4-6-18)20(24)14-23-11-9-16(10-12-23)13-15-1-7-19(22)8-2-15/h1-8,16,20,24H,9-14H2
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/12849400Curator's Comment: description was created based on several sources including :
https://www.ncbi.nlm.nih.gov/pubmed/9918703 | https://www.ncbi.nlm.nih.gov/pubmed/8901012
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12849400
Curator's Comment: description was created based on several sources including :
https://www.ncbi.nlm.nih.gov/pubmed/9918703 | https://www.ncbi.nlm.nih.gov/pubmed/8901012
Eliprodil, also known as SL 82-0715, is a non-competitive NMDA glutamate receptor antagonist, which targets the polyamine modulatory site and is selective for NR2B subunit-containing receptors. Eliprodil was in phase III clinical trial for the treatment of stroke or traumatic brain injury. However, these investigations were failed. One reason suggested for failure was that eliprodil had blocked the synaptic transmission mediated by NMDA receptors, hindering neuronal survival. In addition, eliprodil has been studied in phase II clinical trials for the treatment of Parkinson's disease.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10235551 | https://www.ncbi.nlm.nih.gov/pubmed/8901012 |
Curator's Comment: Pharmacologically, the development of clinically useful NMDA antagonists has been difficult, because many competitive and non-competitive antagonists of this receptor are unable to cross the blood-brain barrier, and many others produce undesirable (psychotomimetic) side effects. Unlike other NMDA antagonists, the polyamine site antagonists, such as eliprodil, partition across the blood-brain barrier and produce their actions at a modulatory site without side effects typical of many non-competitive antagonists.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q13224 Gene ID: 2904.0 Gene Symbol: GRIN2B Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/9519265 |
13.0 nM [Ki] | ||
Target ID: Q99720|||Q7Z653 Gene ID: 10280.0 Gene Symbol: SIGMAR1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/8741023 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Eliprodil Approved UseUnknown |
|||
Primary | Eliprodil Approved UseUnknown |
|||
Primary | Eliprodil Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? | 2002 Oct |
|
Glutamate-dependent regulation of cholinergic phenotype in hypothalamic neurons. | 2003 Dec 19 |
|
The sequential analysis of repeated binary responses: a score test for the case of three time points. | 2006 Jul 15 |
|
Polyamines in the brain: distribution, biological interactions, and their potential therapeutic role in brain ischaemia. | 2007 |
|
Pigment epithelium-derived factor protects retinal ganglion cells. | 2007 Jan 29 |
|
Pharmacology and therapeutic potential of sigma(1) receptor ligands. | 2008 Dec |
|
Alcohol related changes in regulation of NMDA receptor functions. | 2008 Mar |
|
A new homogeneous high-throughput screening assay for profiling compound activity on the human ether-a-go-go-related gene channel. | 2009 Nov 1 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9371155 https://www.ncbi.nlm.nih.gov/pubmed/8741023 https://books.google.ru/books?id=R5JuLXvuIhgC&pg=PA79&lpg=PA79&dq=Eliprodil+intravenous+for+human&source=bl&ots=lT7H9yACSk&sig=xAjBBvTwjbST3fXJoMHIWkhoy2w&hl=ru&sa=X&ved=0ahUKEwi56rDH3bbUAhVLYVAKHc0DC4AQ6AEIIjAA#v=onepage&q=Eliprodil%20intravenous%20for%20human&f=false https://books.google.ca/books?id=uCYg9KUgZiUC&pg=PA248&lpg=PA248&dq=eliprodil+in+human&source=bl&ots=NfQfJSRiAq&sig=ZBkqsb4uHShWJZd2MD6F3IV_qmI&hl=en&sa=X&ved=0ahUKEwiy1d7PiK_UAhUg8YMKHSxgCiY4ChDoAQgnMAA#v=onepage&q=eliprodil%20in%20human&f=true
Curator's Comment: eliprodil is most often administered intravenously, although it has also been used orally in humans and animals, and as an intraperitoneal injection in animals.
IV 1.5 mg and 3.0 mg twice daily for 3 days, IV 5.0 mg and 10.0 mg twice daily for 11 days, IV between 2.5 mg and 10 mg per dose,
or: 3 mg b.i.d for 3 days iv, followed by 10 mg b.i.d for 11 days p.o and 1,5 mg bid for 3 days i.v, then 5 mg b.i.d for 11 days p.o with 3 month follow-up.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8788420
The effect of eliprodil on P-type Ca2+ channels was investigated in acutely dissociated rat Purkinje neurons, by using the whole-cell patch-clamp technique. Eliprodil inhibited in a reversible manner the omega-agatoxin-IVA-sensitive Ba2+ current elicited by step depolarizations from a -80 mV holding voltage (IC50 = 1.9 microM). The Ba2+ current showed steady-state inactivation (V1/2 = -61 mV) which was shifted toward more positive values when the intracellular Ca2+ buffering was increased. In these conditions, the potency of eliprodil was decreased (IC50 = 8.2 microM), suggesting a modulation by intracellular Ca2+ of the eliprodil blockade.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1509
Created by
admin on Sat Dec 16 16:22:04 GMT 2023 , Edited by admin on Sat Dec 16 16:22:04 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
YW62A6TW29
Created by
admin on Sat Dec 16 16:22:04 GMT 2023 , Edited by admin on Sat Dec 16 16:22:04 GMT 2023
|
PRIMARY | |||
|
DB12869
Created by
admin on Sat Dec 16 16:22:04 GMT 2023 , Edited by admin on Sat Dec 16 16:22:04 GMT 2023
|
PRIMARY | |||
|
100000080746
Created by
admin on Sat Dec 16 16:22:04 GMT 2023 , Edited by admin on Sat Dec 16 16:22:04 GMT 2023
|
PRIMARY | |||
|
ELIPRODIL
Created by
admin on Sat Dec 16 16:22:04 GMT 2023 , Edited by admin on Sat Dec 16 16:22:04 GMT 2023
|
PRIMARY | |||
|
SUB06486MIG
Created by
admin on Sat Dec 16 16:22:04 GMT 2023 , Edited by admin on Sat Dec 16 16:22:04 GMT 2023
|
PRIMARY | |||
|
6900
Created by
admin on Sat Dec 16 16:22:04 GMT 2023 , Edited by admin on Sat Dec 16 16:22:04 GMT 2023
|
PRIMARY | |||
|
119431-25-3
Created by
admin on Sat Dec 16 16:22:04 GMT 2023 , Edited by admin on Sat Dec 16 16:22:04 GMT 2023
|
PRIMARY | |||
|
C80994
Created by
admin on Sat Dec 16 16:22:04 GMT 2023 , Edited by admin on Sat Dec 16 16:22:04 GMT 2023
|
PRIMARY | |||
|
DTXSID1045744
Created by
admin on Sat Dec 16 16:22:04 GMT 2023 , Edited by admin on Sat Dec 16 16:22:04 GMT 2023
|
PRIMARY | |||
|
60703
Created by
admin on Sat Dec 16 16:22:04 GMT 2023 , Edited by admin on Sat Dec 16 16:22:04 GMT 2023
|
PRIMARY | |||
|
CHEMBL28564
Created by
admin on Sat Dec 16 16:22:04 GMT 2023 , Edited by admin on Sat Dec 16 16:22:04 GMT 2023
|
PRIMARY | |||
|
C058083
Created by
admin on Sat Dec 16 16:22:04 GMT 2023 , Edited by admin on Sat Dec 16 16:22:04 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)